| [1] Gual P, Giordano S, Anguissola S, et al. Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness[J]. Oncogene, 2001, 20(39):5493-5502.[2] Maulik G, Shrikhande A, Kijima T, et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic in hibition[J]. Cytokine Growth Factor Rev, 2002, 13(1): 41-59.[3] Puri NSalgia R. Synergism of EGFR and c-met pathways, cross-talk and inhibition, in non-small cell lung cancer[J]. J Carcinog, 2008, 7:9.[4] Ketterer K, Kong B, Frank D, et al. Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-met pathway[J]. Cancer Lett, 2009, 277(1):72-81.[5] 俞 维. C-Met和MMP-2在卵巢癌中的表达及相关研究[J]. 中国妇女科临床杂志, 2010, 11(6):440-442[6] Chen YS, Wang JT, Chang YF, et al. Expression of hepatocyte growth factor and c-Met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan[J]. Oral Pathol Med, 2004, 33(4):209-217.[7] Tsai HW, Chow CP, Chan CY, et al. The significance of prohibitin and c-Met/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma[J]. Hum Pathol, 2006, 37(2):198-204.[8] Takeuchi H, Bilchik A, Saha S, et al. c-Met expression level in primary colon cancer:a predictor of tumor invasion and lymph node metastases[J]. Chin Cancer Res, 2003, 9(4):1480-1488.[9] Syed ZA, Yin W, Gill JN, et al. HGF/c-Met signaling during skin tumor cell invasion:indications for a positive feedback loop[J]. BMC Cancer, 2011, 19(11):180-182.[10] 韩 飞, 南欣荣. c-Met、PTEN在甲状腺癌中的表达及其临床意义[J]. 中国医药导报, 2012, 9(22):7-9.[11] Amemiya H, Menolascino F, Pena A. Role of the expression of c-Met receptor in the progression of gastric cancer[J]. Invest Clin, 2010, 51(3):369-380.[12] Drebber U, Baldus SE, Nolden B, et al. The overexpression of c-Met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation[J]. Oncol Rep, 2008, 19(6):1477-1483.[13] Wang JY, Hsieh JS, Chen CC, et al. Alterations of APC, c-Met, and p53 gene in tumor tissue and serum of patients with gastric cancer[J]. J Surg Res, 2004, 120(2):242-248.[14] 张庆飞, 杨 兵. Ezrin和c-Met在胃癌组织中的表达及意义[J]. 山西医科大学学报, 2012, 43(4):257-259.[15] Huang TJ, Wang JT, Lin SR, et al. Overexpression of c-Met protooncogene in human gastric-correlation to clinical feature[J]. Acta Oucol, 2001, 40(5):638-643.[16] Lee J, Seo JW, Jun HJ, et al. Impact of MET amplification on gastric cancer:possible roles as a novel prognostic marker and a potential therapenentic target[J]. Oncol Rep, 2011, 25(6):1517-1524.[17] Horiguchi N, Takayama H, Toyoda M, et al. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met auto-crine activation and enhanced angiogenesis in transgenic micc treated with diethylnitrosamine [J]. Oncogene, 2002, 21(12):1791-1799.[18] Dvies G, Jiang WG, Mason MD. HGF/SF modifies the interaction between c-Met and E-cadherin/catenin complex in prostate cancer cells[J]. Int J Mol Med, 2001, 7:385-388.[19] Yano H, Hara A, Murase S, et al. Expression of hepatocyte growth factor and matrix metalloproteinase-2 in human glioma[J]. Brain tumor Pathol, 2001, 18(1):7-12.[20] Kankuri E, Cholujova D, Comajova M, et al. Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotoes invasiveness of human head and neck carcinoma[J]. Cancer Res, 2005, 65:9914-9922.[21] Date K, Matsumoto K, Kuba K, et al. Inhibition of tumor growth and invasive by a four-kringle antagonist(HGF/NK4) for hepatocyte growth factor[J]. Oncogene, 1998, 17(23):3045-3054.[22] Nakabayashi M, Morishita R, Nakagami H, et al. HGF/NK4 inhibited VEGF-inducted angiogenesis in vitro cultured endothelial cells and in vivo rabbit model[J]. Diabetologia, 2003, 46(1):115-123.[23] Wen J, Matsumoto K, Taniura N, et al. Inhibition of colon cancer growth and metasis by NK4 gene repetitive delivery in mice[J]. Biochem Biophys Res Commun, 2007, 358(1):117-123.[24] Bertotti A, Bracco C, Girolami F, et al. Inhibition of Src impairs the growth of met-addicted gastric tumor[J]. Clin Cancer Res, 2010, 16(15): 3933-3943.[25] Kenessey I, Keszthelyi M, Kramer Z, et al. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma[J]. Curr Cancer Drag Targets, 2010, 10(3):332-342.[26] 冯炜红, 张 斌, 赵洪猛, 等. c-Met抑制剂SGX523诱导乳腺癌MDA-MB-231细胞系的凋亡[J]. 中国肿瘤临床, 2012, 39(2):61-64.[27] Xie B, Xing R, Chen P, et al. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference[J]. J Surg Res, 2010, 162(2):231-238.[28] Michaud NＲ, Jani JP, Hillerman S, et al. Biochemical and pharma-cological characterization of human c-Met neutralizing monoclonal antibody CE-355621[J]. MAbs, 2012, 4(6):710-723. |
